Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST study. (3rd April 2022)

• Record Type: Journal Article
• Authors: Rivera, Raquel; Vilarrasa, E.; Ribera, M.; Roe, E.; Kueder-Pajares, T.; Zayas, A. I.; Martínez-Molina, L.; Mataix Díaz, J.; Rodríguez-Nevado, I. M.; Usero-Bárcena, T.; de la Mano, D.; García-Donoso, C.; Olveira, A.; Guinea, G.; Martín-Vázquez, V.; Ferran, M.
• Is Part Of: Journal of dermatological treatment. Volume 33:Number 3(2022)
• Page Start: 1329
• Page End: 1338
• Publication Date: 2022-04-03
• Subjects: health-related quality of life -- hepatic fibrosis -- hepatic steatosis -- methotrexate -- psoriasis -- Spain; Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.1080/09546634.2020.1801977
• Languages: English
• ISSNs: 0954-6634

Abstract

Abstract: Background: Methotrexate (MTX) is frequently used in the treatment of moderate-to-severe psoriasis, however, there is limited data on health-related quality-of-life (HRQoL), psoriasis clinical outcomes and hepatic fibrosis in MTX-treated patients in routine clinical practice. Objectives: To investigate the impact of moderate-to-severe psoriasis in MTX-treated patients in Spain regarding to HRQoL, psoriasis clinical data and risk of hepatic fibrosis. Methods: Observational, non-interventional, cross-sectional, retrospective, multicentre study, performed in Spain in moderate-to-severe plaque psoriasis patients treated with MTX > 16 weeks prior to inclusion. Results: Despite ongoing treatment, 17.1% of 457 evaluable patients reported moderate-to-extreme impact on HRQoL (DLQI > 5); 21.4% BSA > 5 and 35.2% moderate-to-severe pruritus (VAS ≥ 4). Persistent severe psoriasis (PASI ≥ 10 and/or DLQI ≥ 10) was observed in 10.7%. Hepatic steatosis was identified in 64.1% of patients (HSI ≥ 36) and 37.2% of the patients were at-risk of advanced fibrosis which was associated to the MTX treatment duration. Conclusions: The study identified unmet needs in moderate-to-severe plaque psoriasis patients treated with MTX, revealing a significant proportion of sub-optimally controlled patients in terms of HRQoL and different domains of the disease. This study also found patients at-risk of advanced fibrosis, with evidence suggesting a correlation between longer exposures to MTX and higher risk of advanced fibrosis.